GS
AMLX icon

GTS Securities’s Amylyx Pharmaceuticals AMLX Stock Holding History

GTS Securities’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,403
Closed -$57K – 3899
2024
Q1 		$83.5K Buy
29,403
+3,092
+12% +$40.4K ﹤0.01% 3553
2023
Q4 		$387K Buy
+26,311
New +$403K ﹤0.01% 2996

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

GTS Securities's AMLX Position: Q2 2024 in Review

GTS Securities sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 29,403 shares — an estimated $57K sold.

GTS Securities first reported a position in AMLX in Q4 2023 and held it in 2 quarters. The position peaked at $387K in Q4 2023. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • GTS Securities reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • GTS Securities sold 29,403 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $57K.
  • GTS Securities first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • GTS Securities's Amylyx Pharmaceuticals position peaked at $387K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.